KMT2A and leukemia: Indeed, complete ablation of SMYD2 in the K-Ras/p53-/- model of pancreatic adenocarcinoma [57] and MLL/AF9-N-Ras leukemia model [76] revealed minor delay in the disease onset or no difference in Myc-induced lymphomagenesis [76].